Boots has achieved market share growth for the thirteenth consecutive quarter, with both retail and pharmacy sales showing positive results for the three months ending on May 31, 2024.
Moreover, retail sales saw a notable increase of 6%, building upon a 13% growth in the previous year’s quarter, across all categories. Digital sales also continued their upward trajectory, rising by 13.8% compared to a 25% growth in the same period last year. In-store sales were similarly on the rise, benefiting from increased footfall in flagship, destination health and beauty, and travel stores.
Furthermore, pharmacy sales experienced a growth of 5.8% in the quarter, attributed to the increased uptake of healthcare services. Sebastian James, CEO of Boots UK & ROI, expressed satisfaction with the consistent strong performance, emphasizing the company’s focus on accessibility to new brands and services, value, and customer loyalty.
As Sebastian James looks to depart from his role after six years, Walgreens Boots Alliance has put on hold its plans to sell or list Boots on the stock market. The decision reflects the company’s recognition of Boots’ growth, strategic strength, and positive cashflow as key assets. According to reports from Sky News, James will transition to lead Veonet, a chain of ophthalmology clinics, starting from November.
